<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015742</url>
  </required_header>
  <id_info>
    <org_study_id>HORCSCT-0902</org_study_id>
    <nct_id>NCT01015742</nct_id>
  </id_info>
  <brief_title>Unrelated Double Umbilical Cord Blood Units Transplantation</brief_title>
  <official_title>Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and feasibility of unrelated double
      umbilical cord blood units Transplantation in patients with haematological malignancies using
      Antithymocyte Globulin Cyclophosphamide, busulfan as conditioning and cyclosporin,
      methylprednisolone as GVHD prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies</measure>
    <time_frame>Until end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil and platelet engraftment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of acute graft-vs-host disease(GvHD</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early transplant related mortality</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease free survival at one years</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem cell Transplant using two unrelated umbilical cord blood units.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stem cell Transplantation</intervention_name>
    <description>Busulfan: 3.2 mg/kg IV daily on days -7 to -4
Cyclophosphamide : 60 mg/mÂ² daily on days -3 to -2
Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2
Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90
Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematologically &amp; Histologically confirmed acute lymphoblastic or acute and chronic
             myeloid leukemia in Remission

          -  Aged 1 year to 50 years

          -  Absence of HLA compatible related or other related donor.

          -  Availability of suitable UCB units.

          -  karnofsky performance score (&gt; 12 yr) or lansky play performance(&lt;12 yr) : 80- 100

          -  Adequate renal function defined as:Serum creatinine &lt;1.5 x normal,

          -  Adequate liver function defined as:Total bilirubin &lt;1.5 x normal, or SGOT (AST) or
             SGPT (ALT) &lt;3.0 x normal

          -  Adequate cardiac function defined as: Ejection fraction &gt;50% by echocardiogram.

          -  Adequate pulmonary function defined as:Uncorrected DLCO 50% by pulmonary function
             test.For children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% on room air

        Exclusion Criteria:

          -  Age: &lt; 1year or &gt; 50 year

          -  Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling or other related
             donor

          -  karnofsky performance score (&gt; 12 yr) or lansky play performance(&lt;12 yr) &lt; 80

          -  HIV positive patients.

          -  Female patients who are pregnant or breast feeding

          -  Life expectancy severely limited by diseases of vital organs other than the disease
             indication for transplant

          -  Serious concurrent untreated infection e.g. active tuberculosis, mycoses or viral
             infection

          -  Serious psychiatric/ psychological disorders

          -  Absence of /inability to provide informed consent

          -  Clinical or Paraclinical evidence of CNS or PNS involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Ali Hamidieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology-Oncology and SCT Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ardeshir Ghavamzadeh, MD</last_name>
    <phone>84902635</phone>
    <phone_ext>+98-21</phone_ext>
    <email>ghavamza@sina.tums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology-Oncology &amp; SCT Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Ali Hamidieh, MD</last_name>
      <phone>84902645</phone>
      <phone_ext>+98-21</phone_ext>
      <email>aahamidieh@sina.tums.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Ardeshir Ghavamzadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Ali Hamidieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omid Modiramani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://horcsct.tums.ac.ir</url>
    <description>Hematology-Oncology and Stem Cell Transplantation Research Center</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

